Exalenz Bioscience Ltd. announced that its BreathID®13C-methacetin breath test (MBT) will be evaluated in two Phase 2b clinical studies sponsored by Bristol-Myers Squibb. The studies are designed to assess the safety and efficacy of its investigational therapy BMS-986036 (PEG-FGF21) in patients with nonalcoholic steatohepatitis (NASH) and either compensated liver cirrhosis, or Stage 3 liver fibrosis. The BreathID platform is already commercially used as a standard of care test for Helicobacter pylori (H. pylori) infection and is currently being tested in two other NASH trials to assess therapeutic response. The BMS-986036 studies are being conducted in the United States and Japan. Participants at select US sites will have the option to participate in a sub-study using MBT to evaluate treatment response of patients receiving BMS-986036 or placebo, an exploratory endpoint in the trial.